<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21822">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059512</url>
  </required_header>
  <id_info>
    <org_study_id>NBK-2901-AMNKM</org_study_id>
    <nct_id>NCT02059512</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease</brief_title>
  <official_title>Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study evaluate the effect of the method of administration of autologous
      bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass
      grafts in the surgical treatment of coronary heart disease, to assess the degree of
      effectiveness depending on the method of transplantation (intramyocardial, Intracoronary).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality associated with the progression of basic disease</measure>
    <time_frame>up to 60 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of functioning grafts in patients with implantation of autologous bone marrow mononuclear cells.</measure>
    <time_frame>up to 60 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>cell Therapy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non cell therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cell therapy 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary artery bypass grafting with administration of autologous bone marrow stem cells</intervention_name>
    <arm_group_label>cell Therapy 1</arm_group_label>
    <arm_group_label>cell therapy 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women from 18 to 80 years

          -  Patients with angina pectoris III-IV functional class

          -  Patients signed informed consent

        Exclusion Criteria:

          -  Intolerance of heparin and HES (hydroxyethyl starch)

          -  Hypothyroidism and hyperthyroidism.

          -  Associated pathology with a projected lifespan limitation to 3 years.

          -  infection  diseases

          -  Simultaneous participation in another study.

          -  Pregnancy.

          -  Severe mental disorder.

          -  Refusal of a patient to participate in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander S Nemkov, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Pavlov State Medical University of St. Petersburg.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander S Nemkov, MD, Ph.D</last_name>
    <phone>8 921 795 00 47</phone>
    <email>nemk_as@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir V Komok</last_name>
    <phone>8 904 632 19 00</phone>
    <email>vladimir_komok@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander S Nemkov, MD, Ph.D</last_name>
      <phone>8 921 795 00 47</phone>
      <email>nemk_as@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Vladimir V Komok</last_name>
      <phone>8 904 632 19 00</phone>
      <email>vladimir_komok@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir V Komok, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey –ê Beliy, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic heart disease</keyword>
  <keyword>autologous bone marrow mononuclear cells</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
